A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

Investigator(s):
Gary Schiller, M.D.;
Organization: 
UCLA
NCT Number: 
Disease Name: 
Beta-Thalassemia
Disease Category: 
Trial Phases: 
Phase 1/2
Trial Status: 
Recruiting
Trial Contact: 

Bruck Habtemariam
(310) 794-0242
BHabtemariam@mednet.ucla.edu